{"ticker": {"uuid": "e956e441-f818-4234-a569-624140496f32", "symbol": "CSTL", "name": "Castle Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVTNKcU5BeXVUTVZ1b3Q5QWt4ckZibTUyV0lyYk9LSUFJeFNtWXpZYXQ4Q0I3MVQ5SThvVDdlNTVpVUp3b1B0c2h0Yl85WDI2Ykx3a1FObnRMWlZFZmktWEJuWjdPUnhQVGJ6MDRqQlFYTElQQmIwbl9Pa1ZkbmRDb0N3NmVLRlBDX3JnVXZBVmFJTnRzU3p1Y0h1UnY5a3NBc2E0ajNTUUtoQjVsdkkzcklIR2d1dF9yREtvcDdB?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T00:49:01+00:00", "published_display": "17 Jul 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts", "summary": "Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 4,172 shares of common stock at a weighted-average price of $22.92 per share on July 14, 2026. These sales were largely executed through family trusts under a pre-arranged Rule 10b5-1 trading plan adopte", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-a4f5065d18f7.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:42:13", "published_display": "16 Jul 2026 20:42", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences receives New York approval for atopic dermatitis test", "summary": "Castle Biosciences (NASDAQ:CSTL) has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's shares are cu", "url": "https://www.investing.com/news/company-news/castle-biosciences-receives-new-york-approval-for-atopic-dermatitis-test-93CH-4791726", "source_name": "Investing.com", "published_at": "2026-07-15T16:10:00", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com", "summary": "Castle Biosciences (NASDAQ: CSTL) has received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's sha", "url": "https://ng.investing.com/news/stock-market-news/castle-biosciences-receives-new-york-approval-for-atopic-dermatitis-test-93CH-2599559", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T03:42:13", "published_display": "15 Jul 2026 03:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle's test classifies patients into two atopic dermatitis profiles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMmVXZm45NzZLVVFxLUh3WVJQeW5uYmJyQ1k3NzV6VTNoV213ai04SUVreTRQYjZlQWdXbVd1RmxyUVdNZE80Q3gyaXBLS01pUHFvdFpwWkNaeVh5ckw2c01QU0ZjY1ZpSnR0RGs4dGlQZ1ZSYldBeGdQLUMweldKU25oU2p3MzUyS0N0X3VxQ05IVGJqRnBvb1dlcDY3XzBBUXpQUjdmR1NtdjFPenVFc1JRMlJoVWhmX0Q0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:30:00+00:00", "published_display": "14 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx\u2122 Test", "summary": "Castle Biosciences has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile test designed to guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. This approval expands access ", "url": "https://www.prnewswire.com/news-releases/castle-biosciences-announces-new-york-state-department-of-health-approval-of-its-advancead-tx-test-302825462.html", "source_name": "PR Newswire", "published_at": "2026-07-14T20:16:15", "published_display": "14 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNakQwVUZEdTRDa01PZy0wQ3lQaU9LRE9DVUZqSXk1RS1OZ2E3UDF4S1lPQVJCcFZPR09GNjMtSE5LZ3RiRXg1Qk80M3JJQUtRT1NXNm9LekxGdUxtSWZlaXVyS1lrRjQ0ZFJrM3I0MWhPTTNjTURKMDB2WGlsZVdyZU9hVDBiNnZiR3ZFbWN6bkN4NlRvcVpTVk9Pa1kxMmROYnhKQlZnZUJWQnFRY19nLXp5eHhGb2ZDUTJCbGVwY18?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T23:34:15+00:00", "published_display": "10 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul", "summary": "Castle Biosciences (CSTL) announced it will release its Q2 2026 financial results on July 30, 2026, after market close, followed by a webcast. GuruFocus assesses CSTL as 19.0% undervalued with a GF Value\u2122 of $29.19 and a strong GF Score\u2122 of 77/100, driven by excellent financial s", "url": "https://www.gurufocus.com/news/8951476/castle-biosciences-cstl-to-release-q2-financial-results-on-july-30-2026", "source_name": "GuruFocus", "published_at": "2026-07-09T14:13:20", "published_display": "09 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026", "summary": "Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. Following the release, company management will host a webcast at 4:30 p.m. Eastern time to discuss the results and conduct a ", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-release-second-quarter-110000905.html", "source_name": "Market source", "published_at": "2026-07-09T11:13:20", "published_display": "09 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences sets July 30 webcast for Q2 results", "summary": "Castle Biosciences (Nasdaq: CSTL) will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a webcast at 4:30 p.m. Eastern time to discuss these results, followed by a Q&A session. A prior earnings-date notice resu", "url": "https://www.stocktitan.net/news/CSTL/castle-biosciences-to-release-second-quarter-2026-financial-results-xxeesv22i6ug.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:42:25", "published_display": "09 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows", "summary": "Castle Biosciences is refining its melanoma testing strategy to meet the increasing demand for precise diagnostic tools in cancer. The company specializes in molecular diagnostics for skin cancers and solid tumors, focusing on tests that assess the risk of melanoma recurrence or ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/castle-biosciences-updates-its-melanoma-testing-strategy-as-diagnostics/69725711", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:40:56", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Castle Biosciences Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Castle Biosciences Inc. on July 6. The content is primarily a placeholder or metadata posting rather than a detailed news report, indicated by the repetitive title and a lack of specific financial details beyond general market data. It ", "url": "https://ng.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-for-6-july-93CH-2587581", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T21:32:00", "published_display": "06 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock", "summary": "Derek Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ: CSTL), sold 9,834 shares of company stock for approximately $238,916 through direct and indirect trusts, as reported in an SEC filing. Concurrently, he acquired 6,214 shares by exercising stock options as part ", "url": "https://www.investing.com/news/insider-trading-news/derek-maetzold-pres--ceo-sells-238916-of-castle-biosciences-stock-93CH-4777452", "source_name": "Investing.com", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan", "summary": "Castle Biosciences CEO Derek Maetzold, through associated entities, sold 9,836 shares of common stock at a weighted-average price of $24.29 per share on July 1, 2026, pursuant to a pre-arranged Rule 10b5-1 plan. Concurrently, he exercised options for 6,214 shares at $2.39 each. T", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-9da9ddf63953.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan", "summary": "Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold a total of 8,586 shares of Common Stock on July 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold in two weighted-average price transactions at $24.40 and $24.78 per share. Foll", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-433f711a0b6e.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (CSTL) That Institutions Follow", "summary": "This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), highlighting strong sentiment across all time horizons supporting an overweight bias. It details several AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and st", "url": "https://news.stocktradersdaily.com/news_release/22/The_Technical_Signals_Behind_CSTL_That_Institutions_Follow_070626041002_1783368602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T16:10:00", "published_display": "06 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Castle Biosciences, Inc. \u2013 NASDAQ:CSTL", "summary": "The article focuses on the enterprise value to forward revenue of Castle Biosciences, Inc. (NASDAQ: CSTL). It appears to be a financial data point presented within the context of TradingView's platform, indicating analytical information for investors and traders.", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:10:38", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Castle Biosciences For: 1 July By Investing.com", "summary": "This article announces the filing of Form 144 for Castle Biosciences (CSTL) on July 1st. It also includes current stock market data and various financial news headlines from Investing.com. The company's stock symbol is CSTL, and it shows a 3.61% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-144-castle-biosciences-for-1-july-93CH-4717219", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:09:20", "published_display": "01 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maetzold family Rule 144 sales reported for CSTL (CSTL) \u2014 multiple small lots", "summary": "Multiple Rule 144 sale notices by Derek Maetzold and related trusts regarding CASTLE BIOSCIENCES INC (CSTL) have been reported, listing numerous small open-market dispositions of Common shares between April and June 2026. The sales, which include those from trusts like The Maetzo", "url": "https://www.stocktitan.net/sec-filings/CSTL/144-castle-biosciences-inc-sec-filing-2155748fc5a1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:20", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones", "summary": "This article provides a precision trading analysis for Castle Biosciences Inc. (CSTL) as of June 25, 2026, highlighting a strong near-term sentiment with a long-term positive bias. It details an exceptional risk-reward setup targeting a 46.0% gain versus a 0.3% risk, along with s", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Castle_Biosciences_Inc._CSTL_Risk_Zones_062526030202_1782414122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T11:40:46", "published_display": "27 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086)", "summary": "This article provides an overview of Castle Biosciences, Inc. (TRADEGATE:086) financial actuals and estimates, including income statement, balance sheet, and cash flow data, as well as analyst price targets. It also includes frequently asked questions regarding the company's stoc", "url": "https://www.tradingview.com/symbols/TRADEGATE-086/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:50", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL)", "summary": "This article provides an overview of Castle Biosciences, Inc. (NASDAQ:CSTL) stock performance, financial estimates, and analyst forecasts. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, along with insights", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:32", "published_display": "26 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down", "summary": "Analyst price targets for Castle Biosciences (CSTL) have seen mixed revisions, with some targets lowered from the US$50 range to the mid-US$30s and US$40s, reflecting a more cautious outlook on growth and profitability. While some analysts maintain a \"Buy\" rating, citing strong r", "url": "https://finance.yahoo.com/markets/stocks/articles/castle-biosciences-cstl-stock-sees-100738648.html", "source_name": "Market source", "published_at": "2026-06-26T06:07:00", "published_display": "26 Jun 2026 06:07", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal", "summary": "Castle Biosciences' Chief Financial Officer, Frank Stokes, has been recognized as a 2026 CFO Awards honoree by the Houston Business Journal. This award acknowledges his financial leadership and contributions, including guiding the company through its Nasdaq IPO and multiple strat", "url": "https://www.nasdaq.com/press-release/castle-biosciences-chief-financial-officer-frank-stokes-named-2026-cfo-awards-honoree", "source_name": "Nasdaq", "published_at": "2026-06-25T23:10:27", "published_display": "25 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences\u2019 melanoma test outperforms risk tool", "summary": "Castle Biosciences (NASDAQ:CSTL) announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the Melanoma Institute Australia nomogram in identifying low and high-risk melanoma patients, as published in Dermatology and Therapy. The company, with a strong gross", "url": "https://www.investing.com/news/company-news/castle-biosciences-melanoma-test-outperforms-risk-tool-93CH-4761535", "source_name": "Investing.com", "published_at": "2026-06-25T21:11:07", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Castle Biosciences at Buy", "summary": "Roth Capital has initiated coverage on Castle Biosciences with a \"Buy\" rating. This indicates a positive outlook from the investment firm regarding the company's stock. Investors will be watching for further details on the rationale behind this rating.", "url": "https://www.moomoo.com/news/post/72033704/roth-capital-initiates-castle-biosciences-at-buy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T20:11:32", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences test better spots melanoma patients who may skip surgery", "summary": "Castle Biosciences announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the MIA nomogram in a prospective, multicenter study for identifying cutaneous melanoma patients who could safely avoid sentinel lymph node biopsy (SLNB). The i31-SLNB test accurate", "url": "https://www.stocktitan.net/news/CSTL/decision-dx-melanoma-s-i31-slnb-outperforms-mia-nomogram-in-erif5d5x3mfl.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Castle Biosciences, Inc. \u2013 NASDAQ:CSTL", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Castle Biosciences, Inc. (NASDAQ: CSTL) as listed on TradingView. It appears to be a financial data snippet rather than a comprehensive article, indicating a reporting of this specific financial ratio for t", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-reports-inducement-grants-110000835.html", "source_name": "PR Newswire", "published_at": "2026-06-19T11:00:00+00:00", "published_display": "19 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences awards RSUs to 172 employees in hiring push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNYnpyQmJfS3o4UDRZcDVzdTBXeDV4MTBMMHpkSmsyVkd0VkFOdjBZRjREaDNFTC1zWFFybUxmcDFjMGVuZnN6c3pxcTVlMFdCV1g2VkFiRktMeFZyUGxQQWJFdVRsalFuSXNOMzB5SmFPMm4zTlVnSTFYU2hhbU4wWGVGN09LQ3lHTkV1M205clhuaWdfb0dXQ3RHVmxYU1lwMUdiZF9DZGczVGk4MGc4SmR4cTdwS0JaWDk2cQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNYzQ5d0JYRHRWbk9ENjFnRkNpLXl3X2FFcVFYOVp2SjZvT1VNS1VyR1ViU00yZXhjbEhVR2xCODRkdnpTdkJkNll6eFcyNDV4NWtxeGQwcnN0SjQ0aTlDRmlMTG5FU1lNUk50NURjMXNNcm5TcVo3bndIalJYc2o2MDFxNmlOWDdCMFJfRHd6aVVZZjhsZ0JidENTc3VfV09VdHZzMzU0NV90dlVFUjkyRmdpdXcxaWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences' TissueCypher\u00ae Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-tissuecypher-test-surpasses-110000794.html", "source_name": "PR Newswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQanF3dlI4bks0YmdOMjBiUnFuYm9RR3FTLXltMjRoRHI0UlQ2VnZqdnl2STZLbzNtZjdQLTR1dHNWVzdtTEMxS05xSk1HU0RnZkJKYkhCdEZ1TTF0Q0N6M3lGX1gxY3ViREZVQkR3dlNPbWdIY3Jjak9oRng3TjBycElueEM5dVFIOENGNUh0enN0RVBpODFDWnNsSE5LZ2hwbzktVlNyOHI?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcW42SXFxM1dnUDhKQnJDQWJUNGh2em5iWGxIcjFCd2RkMnY5TjhubW9rbV9BQlRZU1NXWVFza0hROXRmdFVfanNCTV9ScWJOcy01aFhtOW4tMk9LaVY2c1hrcVpwMzBITWVxaXpWenZuOTdTOUpnZ1lnZ2hVd0VGMHliOElPZElBTVdyUW51TXM0dFBhMm15TWk0blhwekxzRzQ0WHFB?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) Q1 Loss Of US$14.5 Million Tests Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOYWMtU05FQW5leVdESUtGUVNXWThfQk9xZ2plcnEwczktNWtuU1g1YzcyVFQ1Ni03U0l4VU1sMTRuSElJYmdieTdpNW02eWhZRHlCaW1IQngwdU1jMHdwQm5hSGhwelpTN3lPMUV1X0dudzNINm13cmlMSnNZMGZDNGJVckZ5NWxEUzlYR0pKc09xNjFMZEdEZE5scGxFdXliZjNnT0w3cw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQa2ZnT25fbVhMSXVMUGpGY2h1VGFmSTNZbzVCcmVjQ0IwNXRxVWZKdkRKdzdUSVUwbDBFNVRwUFZ0Yl9GYXQzdjUySTJicFowdHVuc19vQlpBVjlIZ2xPUEs0dmVaYzFxMmpWNzVRWEpId0p6MFpESE41bnRhNm5NOTZTRUVNZG85Y01HQ3VvR1R0cEY2SGQ5RlRUdFpiN19VWGRNN0hDdw?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTkp3d2oxLVRQQlJxXzRqVGg4SEpsdHEybTMwMlgzTVFFcWZnNGRWNU9FeVYyTlA4ZVlvc3NvVzRHSFk4RXVGRnc0OThVVFJnTnFZWmVHUVBIVEhVTzJHQVdPUU44MjZJSzd2eTMySTFnSU5TODR6RUxYWC1kNWFFNHozZFJld1dha3hfdUhfamU0ajA?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVTNKcU5BeXVUTVZ1b3Q5QWt4ckZibTUyV0lyYk9LSUFJeFNtWXpZYXQ4Q0I3MVQ5SThvVDdlNTVpVUp3b1B0c2h0Yl85WDI2Ykx3a1FObnRMWlZFZmktWEJuWjdPUnhQVGJ6MDRqQlFYTElQQmIwbl9Pa1ZkbmRDb0N3NmVLRlBDX3JnVXZBVmFJTnRzU3p1Y0h1UnY5a3NBc2E0ajNTUUtoQjVsdkkzcklIR2d1dF9yREtvcDdB?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T00:49:01+00:00", "published_display": "17 Jul 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts", "summary": "Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 4,172 shares of common stock at a weighted-average price of $22.92 per share on July 14, 2026. These sales were largely executed through family trusts under a pre-arranged Rule 10b5-1 trading plan adopte", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-a4f5065d18f7.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:42:13", "published_display": "16 Jul 2026 20:42", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences receives New York approval for atopic dermatitis test", "summary": "Castle Biosciences (NASDAQ:CSTL) has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's shares are cu", "url": "https://www.investing.com/news/company-news/castle-biosciences-receives-new-york-approval-for-atopic-dermatitis-test-93CH-4791726", "source_name": "Investing.com", "published_at": "2026-07-15T16:10:00", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com", "summary": "Castle Biosciences (NASDAQ: CSTL) has received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy selection for moderate-to-severe atopic dermatitis patients. The company's sha", "url": "https://ng.investing.com/news/stock-market-news/castle-biosciences-receives-new-york-approval-for-atopic-dermatitis-test-93CH-2599559", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T03:42:13", "published_display": "15 Jul 2026 03:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle's test classifies patients into two atopic dermatitis profiles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMmVXZm45NzZLVVFxLUh3WVJQeW5uYmJyQ1k3NzV6VTNoV213ai04SUVreTRQYjZlQWdXbVd1RmxyUVdNZE80Q3gyaXBLS01pUHFvdFpwWkNaeVh5ckw2c01QU0ZjY1ZpSnR0RGs4dGlQZ1ZSYldBeGdQLUMweldKU25oU2p3MzUyS0N0X3VxQ05IVGJqRnBvb1dlcDY3XzBBUXpQUjdmR1NtdjFPenVFc1JRMlJoVWhmX0Q0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:30:00+00:00", "published_display": "14 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx\u2122 Test", "summary": "Castle Biosciences has received New York State Department of Health approval for its AdvanceAD-Tx test, a non-invasive gene expression profile test designed to guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. This approval expands access ", "url": "https://www.prnewswire.com/news-releases/castle-biosciences-announces-new-york-state-department-of-health-approval-of-its-advancead-tx-test-302825462.html", "source_name": "PR Newswire", "published_at": "2026-07-14T20:16:15", "published_display": "14 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNakQwVUZEdTRDa01PZy0wQ3lQaU9LRE9DVUZqSXk1RS1OZ2E3UDF4S1lPQVJCcFZPR09GNjMtSE5LZ3RiRXg1Qk80M3JJQUtRT1NXNm9LekxGdUxtSWZlaXVyS1lrRjQ0ZFJrM3I0MWhPTTNjTURKMDB2WGlsZVdyZU9hVDBiNnZiR3ZFbWN6bkN4NlRvcVpTVk9Pa1kxMmROYnhKQlZnZUJWQnFRY19nLXp5eHhGb2ZDUTJCbGVwY18?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T23:34:15+00:00", "published_display": "10 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul", "summary": "Castle Biosciences (CSTL) announced it will release its Q2 2026 financial results on July 30, 2026, after market close, followed by a webcast. GuruFocus assesses CSTL as 19.0% undervalued with a GF Value\u2122 of $29.19 and a strong GF Score\u2122 of 77/100, driven by excellent financial s", "url": "https://www.gurufocus.com/news/8951476/castle-biosciences-cstl-to-release-q2-financial-results-on-july-30-2026", "source_name": "GuruFocus", "published_at": "2026-07-09T14:13:20", "published_display": "09 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026", "summary": "Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. Following the release, company management will host a webcast at 4:30 p.m. Eastern time to discuss the results and conduct a ", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-release-second-quarter-110000905.html", "source_name": "Market source", "published_at": "2026-07-09T11:13:20", "published_display": "09 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences sets July 30 webcast for Q2 results", "summary": "Castle Biosciences (Nasdaq: CSTL) will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a webcast at 4:30 p.m. Eastern time to discuss these results, followed by a Q&A session. A prior earnings-date notice resu", "url": "https://www.stocktitan.net/news/CSTL/castle-biosciences-to-release-second-quarter-2026-financial-results-xxeesv22i6ug.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:42:25", "published_display": "09 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows", "summary": "Castle Biosciences is refining its melanoma testing strategy to meet the increasing demand for precise diagnostic tools in cancer. The company specializes in molecular diagnostics for skin cancers and solid tumors, focusing on tests that assess the risk of melanoma recurrence or ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/castle-biosciences-updates-its-melanoma-testing-strategy-as-diagnostics/69725711", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:40:56", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Castle Biosciences Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Castle Biosciences Inc. on July 6. The content is primarily a placeholder or metadata posting rather than a detailed news report, indicated by the repetitive title and a lack of specific financial details beyond general market data. It ", "url": "https://ng.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-for-6-july-93CH-2587581", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T21:32:00", "published_display": "06 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock", "summary": "Derek Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ: CSTL), sold 9,834 shares of company stock for approximately $238,916 through direct and indirect trusts, as reported in an SEC filing. Concurrently, he acquired 6,214 shares by exercising stock options as part ", "url": "https://www.investing.com/news/insider-trading-news/derek-maetzold-pres--ceo-sells-238916-of-castle-biosciences-stock-93CH-4777452", "source_name": "Investing.com", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan", "summary": "Castle Biosciences CEO Derek Maetzold, through associated entities, sold 9,836 shares of common stock at a weighted-average price of $24.29 per share on July 1, 2026, pursuant to a pre-arranged Rule 10b5-1 plan. Concurrently, he exercised options for 6,214 shares at $2.39 each. T", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-9da9ddf63953.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan", "summary": "Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold a total of 8,586 shares of Common Stock on July 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold in two weighted-average price transactions at $24.40 and $24.78 per share. Foll", "url": "https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-433f711a0b6e.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:25", "published_display": "06 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (CSTL) That Institutions Follow", "summary": "This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), highlighting strong sentiment across all time horizons supporting an overweight bias. It details several AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and st", "url": "https://news.stocktradersdaily.com/news_release/22/The_Technical_Signals_Behind_CSTL_That_Institutions_Follow_070626041002_1783368602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T16:10:00", "published_display": "06 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Castle Biosciences, Inc. \u2013 NASDAQ:CSTL", "summary": "The article focuses on the enterprise value to forward revenue of Castle Biosciences, Inc. (NASDAQ: CSTL). It appears to be a financial data point presented within the context of TradingView's platform, indicating analytical information for investors and traders.", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:10:38", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Castle Biosciences For: 1 July By Investing.com", "summary": "This article announces the filing of Form 144 for Castle Biosciences (CSTL) on July 1st. It also includes current stock market data and various financial news headlines from Investing.com. The company's stock symbol is CSTL, and it shows a 3.61% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-144-castle-biosciences-for-1-july-93CH-4717219", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:09:20", "published_display": "01 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maetzold family Rule 144 sales reported for CSTL (CSTL) \u2014 multiple small lots", "summary": "Multiple Rule 144 sale notices by Derek Maetzold and related trusts regarding CASTLE BIOSCIENCES INC (CSTL) have been reported, listing numerous small open-market dispositions of Common shares between April and June 2026. The sales, which include those from trusts like The Maetzo", "url": "https://www.stocktitan.net/sec-filings/CSTL/144-castle-biosciences-inc-sec-filing-2155748fc5a1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:20", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones", "summary": "This article provides a precision trading analysis for Castle Biosciences Inc. (CSTL) as of June 25, 2026, highlighting a strong near-term sentiment with a long-term positive bias. It details an exceptional risk-reward setup targeting a 46.0% gain versus a 0.3% risk, along with s", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Castle_Biosciences_Inc._CSTL_Risk_Zones_062526030202_1782414122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T11:40:46", "published_display": "27 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086)", "summary": "This article provides an overview of Castle Biosciences, Inc. (TRADEGATE:086) financial actuals and estimates, including income statement, balance sheet, and cash flow data, as well as analyst price targets. It also includes frequently asked questions regarding the company's stoc", "url": "https://www.tradingview.com/symbols/TRADEGATE-086/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:50", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL)", "summary": "This article provides an overview of Castle Biosciences, Inc. (NASDAQ:CSTL) stock performance, financial estimates, and analyst forecasts. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, along with insights", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:32", "published_display": "26 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down", "summary": "Analyst price targets for Castle Biosciences (CSTL) have seen mixed revisions, with some targets lowered from the US$50 range to the mid-US$30s and US$40s, reflecting a more cautious outlook on growth and profitability. While some analysts maintain a \"Buy\" rating, citing strong r", "url": "https://finance.yahoo.com/markets/stocks/articles/castle-biosciences-cstl-stock-sees-100738648.html", "source_name": "Market source", "published_at": "2026-06-26T06:07:00", "published_display": "26 Jun 2026 06:07", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal", "summary": "Castle Biosciences' Chief Financial Officer, Frank Stokes, has been recognized as a 2026 CFO Awards honoree by the Houston Business Journal. This award acknowledges his financial leadership and contributions, including guiding the company through its Nasdaq IPO and multiple strat", "url": "https://www.nasdaq.com/press-release/castle-biosciences-chief-financial-officer-frank-stokes-named-2026-cfo-awards-honoree", "source_name": "Nasdaq", "published_at": "2026-06-25T23:10:27", "published_display": "25 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences\u2019 melanoma test outperforms risk tool", "summary": "Castle Biosciences (NASDAQ:CSTL) announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the Melanoma Institute Australia nomogram in identifying low and high-risk melanoma patients, as published in Dermatology and Therapy. The company, with a strong gross", "url": "https://www.investing.com/news/company-news/castle-biosciences-melanoma-test-outperforms-risk-tool-93CH-4761535", "source_name": "Investing.com", "published_at": "2026-06-25T21:11:07", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Castle Biosciences at Buy", "summary": "Roth Capital has initiated coverage on Castle Biosciences with a \"Buy\" rating. This indicates a positive outlook from the investment firm regarding the company's stock. Investors will be watching for further details on the rationale behind this rating.", "url": "https://www.moomoo.com/news/post/72033704/roth-capital-initiates-castle-biosciences-at-buy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T20:11:32", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences test better spots melanoma patients who may skip surgery", "summary": "Castle Biosciences announced that its DecisionDx-Melanoma i31-SLNB test significantly outperformed the MIA nomogram in a prospective, multicenter study for identifying cutaneous melanoma patients who could safely avoid sentinel lymph node biopsy (SLNB). The i31-SLNB test accurate", "url": "https://www.stocktitan.net/news/CSTL/decision-dx-melanoma-s-i31-slnb-outperforms-mia-nomogram-in-erif5d5x3mfl.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Castle Biosciences, Inc. \u2013 NASDAQ:CSTL", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Castle Biosciences, Inc. (NASDAQ: CSTL) as listed on TradingView. It appears to be a financial data snippet rather than a comprehensive article, indicating a reporting of this specific financial ratio for t", "url": "https://www.tradingview.com/symbols/NASDAQ-CSTL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-reports-inducement-grants-110000835.html", "source_name": "PR Newswire", "published_at": "2026-06-19T11:00:00+00:00", "published_display": "19 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences awards RSUs to 172 employees in hiring push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNYnpyQmJfS3o4UDRZcDVzdTBXeDV4MTBMMHpkSmsyVkd0VkFOdjBZRjREaDNFTC1zWFFybUxmcDFjMGVuZnN6c3pxcTVlMFdCV1g2VkFiRktMeFZyUGxQQWJFdVRsalFuSXNOMzB5SmFPMm4zTlVnSTFYU2hhbU4wWGVGN09LQ3lHTkV1M205clhuaWdfb0dXQ3RHVmxYU1lwMUdiZF9DZGczVGk4MGc4SmR4cTdwS0JaWDk2cQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNYzQ5d0JYRHRWbk9ENjFnRkNpLXl3X2FFcVFYOVp2SjZvT1VNS1VyR1ViU00yZXhjbEhVR2xCODRkdnpTdkJkNll6eFcyNDV4NWtxeGQwcnN0SjQ0aTlDRmlMTG5FU1lNUk50NURjMXNNcm5TcVo3bndIalJYc2o2MDFxNmlOWDdCMFJfRHd6aVVZZjhsZ0JidENTc3VfV09VdHZzMzU0NV90dlVFUjkyRmdpdXcxaWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences' TissueCypher\u00ae Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/castle-biosciences-tissuecypher-test-surpasses-110000794.html", "source_name": "PR Newswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQanF3dlI4bks0YmdOMjBiUnFuYm9RR3FTLXltMjRoRHI0UlQ2VnZqdnl2STZLbzNtZjdQLTR1dHNWVzdtTEMxS05xSk1HU0RnZkJKYkhCdEZ1TTF0Q0N6M3lGX1gxY3ViREZVQkR3dlNPbWdIY3Jjak9oRng3TjBycElueEM5dVFIOENGNUh0enN0RVBpODFDWnNsSE5LZ2hwbzktVlNyOHI?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcW42SXFxM1dnUDhKQnJDQWJUNGh2em5iWGxIcjFCd2RkMnY5TjhubW9rbV9BQlRZU1NXWVFza0hROXRmdFVfanNCTV9ScWJOcy01aFhtOW4tMk9LaVY2c1hrcVpwMzBITWVxaXpWenZuOTdTOUpnZ1lnZ2hVd0VGMHliOElPZElBTVdyUW51TXM0dFBhMm15TWk0blhwekxzRzQ0WHFB?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences (CSTL) Q1 Loss Of US$14.5 Million Tests Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOYWMtU05FQW5leVdESUtGUVNXWThfQk9xZ2plcnEwczktNWtuU1g1YzcyVFQ1Ni03U0l4VU1sMTRuSElJYmdieTdpNW02eWhZRHlCaW1IQngwdU1jMHdwQm5hSGhwelpTN3lPMUV1X0dudzNINm13cmlMSnNZMGZDNGJVckZ5NWxEUzlYR0pKc09xNjFMZEdEZE5scGxFdXliZjNnT0w3cw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQa2ZnT25fbVhMSXVMUGpGY2h1VGFmSTNZbzVCcmVjQ0IwNXRxVWZKdkRKdzdUSVUwbDBFNVRwUFZ0Yl9GYXQzdjUySTJicFowdHVuc19vQlpBVjlIZ2xPUEs0dmVaYzFxMmpWNzVRWEpId0p6MFpESE41bnRhNm5NOTZTRUVNZG85Y01HQ3VvR1R0cEY2SGQ5RlRUdFpiN19VWGRNN0hDdw?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTkp3d2oxLVRQQlJxXzRqVGg4SEpsdHEybTMwMlgzTVFFcWZnNGRWNU9FeVYyTlA4ZVlvc3NvVzRHSFk4RXVGRnc0OThVVFJnTnFZWmVHUVBIVEhVTzJHQVdPUU44MjZJSzd2eTMySTFnSU5TODR6RUxYWC1kNWFFNHozZFJld1dha3hfdUhfamU0ajA?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 93, "total_relevant": 39, "sentiment_summary": {"positive": 12, "negative": 6, "neutral": 21, "score": 55, "total": 39, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 24.16, "latest_week": "2026-07-17", "one_week_move": 1.9, "four_week_move": 14.4, "twelve_week_move": -1.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.417835, "market_dynamics_buy_signal": false, "relative_strength": -20.474098, "fair_value_gap": 0.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0924, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.9% over one week, +14.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 4}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 8}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.9% over one week, +14.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com"}], "updated_at": "2026-07-19T18:11:20.322784+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}